 The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc NASDAQ: PSTX hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy. The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer mCRPC. 